$4,750.00
The market for molecular in vitro diagnostic and screening tests for oncology totaled approximately $1.0bn in 2017, and is projected to expand at a compound annual growth rate (CAGR) of 13.1% during 2017-22, reaching an estimated $1.9bn.
The market for molecular in vitro diagnostic and screening tests for oncology totaled approximately $1.0bn in 2017, and is projected to expand at a compound annual growth rate (CAGR) of 13.1% during 2017-22, reaching an estimated $1.9bn. Geographic segments covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Due to geographic trends in cancer incidence, there is considerable variation in market growth from one country/region to another. The greatest growth is projected for the RoW markets (at a 17.4% CAGR), followed by the US (14.1%), the 5EU countries (9.2%), and Japan (8.5%).
Table of Contents
Executive Summary………………………………………………………………………………………………… ES-1
i. Molecular diagnostics market for oncology …………………………………………………………………..ES-1
a. Selected market drivers and limiters…………………………………………………………ES-5
b. Market leaders……………………………………………………………………………………….ES-6
ii. Methodology …………………………………………………………………………………………………………..ES-6
Exhibit ES-1: Global market for molecular in vitro diagnostic tests for infectious disease, oncology, genetic testing, and blood screening, by segment ($m), 2017 and 2022 ….. ES-1
Exhibit ES-2: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by type of cancer, 2017-22………………………………………………………………………………….ES-3
Exhibit ES-3: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by region, 2017-22…………………………………………………………………………………………….ES-4
1. Market Environment……………………………………………………………………………………………. 1-1
1.1 Overview of molecular in vitro diagnostics…………………………………………………………………. 1-2
1.2 Market trends…………………………………………………………………………………………………………. 1-4
1.2.1 Advantages of molecular cancer testing versus immunochemical and biochemical methods…………………………………………………………………. 1-4
1.2.2 Companion diagnostics and pharmacogenomics…………………………………….. 1-6
1.2.3 Reimbursement ………………………………………………………………………………… 1-10
1.2.4 Regulatory issues………………………………………………………………………………. 1-10
1.2.5 Liability issues …………………………………………………………………………………… 1-11
1.3 Target market segments for molecular cancer diagnostics…………………………………………. 1-12
1.4 Bibliography…………………………………………………………………………………………………………. 1-13
Exhibit 1-1: Global market for molecular in vitro diagnostic tests for infectious disease, oncology, genetic testing, and blood screening, by segment ($m), 2017 and 2022 …….1-1
Exhibit 1-2: Selected molecular in vitro diagnostic tests for oncology, 2018 ……………………………….. 1-3
Exhibit 1-3: Range of applicability of biochemical assay, immunochemical, and molecular testing in oncology applications…………………………………………………………………………………………. 1-5
Exhibit 1-4: Selected molecular companion diagnostic tests and associated targeted therapies……. 1-8
2. Cancer Incidence and Prevalence by Type………………………………………………………………. 2-1
2.1 Breast cancer…………………………………………………………………………………………………………. 2-8
2.2 Prostate cancer………………………………………………………………………………………………………. 2-8
2.3 Lung cancer……………………………………………………………………………………………………………. 2-9
2.4 Colorectal cancer…………………………………………………………………………………………………… 2-9
2.5 Melanoma…………………………………………………………………………………………………………… 2-10
2.6 Pancreatic cancer…………………………………………………………………………………………………. 2-10
2.7 Hepatocellular cancer…………………………………………………………………………………………… 2-11
2.8 Cervical cancer…………………………………………………………………………………………………….. 2-12
2.9 Oral cancer………………………………………………………………………………………………………….. 2-12
2.10 Leukemia and lymphoma …………………………………………………………………………………….. 2-13
2.11 Stomach cancer ………………………………………………………………………………………………….. 2-13
2.12 Bibliography……………………………………………………………………………………………………….. 2-14
Exhibit 2-1: Cancer incidence by country/region, 2015…………………………………………………………2-2
Exhibit 2-2: Cancer incidence by country/region, 2020…………………………………………………………….. 2-3
Exhibit 2-3: Cancer incidence by country/region, 2025…………………………………………………………….. 2-4
Exhibit 2-4: Cancer incidence forecast, by country/region, 2015-25…………………………………………… 2-5
Exhibit 2-5: Cancer prevalence, by country/region, 2012………………………………………………………….. 2-7
3. Analytical Platforms for Molecular In Vitro Diagnostics for Oncology ………………………… 3-1
3.1 Polymerase chain reaction and other nucleic acid amplification technologies……………….. 3-4
3.2 In situ hybridization………………………………………………………………………………………………… 3-6
3.3 Immunohistochemistry …………………………………………………………………………………………… 3-6
3.4 Next-generation sequencing ……………………………………………………………………………………. 3-7
3.5 Microarrays……………………………………………………………………………………………………………. 3-9
3.6 Flow cytometry…………………………………………………………………………………………………….. 3-10
3.7 Other molecular diagnostic technologies…………………………………………………………………. 3-11
3.8 Bibliography…………………………………………………………………………………………………………. 3-13
Exhibit 3-1: Types of analytical platforms employed in molecular cancer diagnostics, 2018 ………… 3-2
Exhibit 3-2: Selected next-generation sequencing technologies, 2018 ……………………………………….. 3-8
4. Molecular In Vitro Diagnostic and Screening Tests for Oncology………………………………… 4-1
4.1 Market drivers and limiters……………………………………………………………………………………… 4-1
4.2 End-user characteristics ………………………………………………………………………………………….. 4-5
4.3 Market for molecular diagnostics, by cancer type and geographic region……………………… 4-6
4.3.1 Breast cancer molecular IVD market, by geographic region …………………….. 4-9
4.3.2 Prostate cancer molecular diagnostics market, by region………………………. 4-10
4.3.3 Lung cancer molecular diagnostics market, by region……………………………. 4-13
4.3.4 Colorectal cancer molecular diagnostics market, by region……………………. 4-15
4.3.5 Melanoma molecular diagnostics market, by region …………………………….. 4-17
4.3.6 Hepatocellular cancer molecular diagnostics market, by region……………… 4-19
4.3.7 Pancreatic cancer molecular diagnostics market, by region …………………… 4-19
4.3.8 Cervical cancer molecular diagnostics market, by region……………………….. 4-20
4.3.9 Leukemia and lymphoma molecular diagnostics market, by region ………… 4-22
4.3.10 Stomach cancer molecular diagnostics market, by region ……………………. 4-24
4.3.11 Market for molecular diagnostic products for other cancer types, by region ………………………………………………………………………………………. 4-24
4.4 Competitive analysis……………………………………………………………………………………………… 4-27
4.4.1 Company sales by cancer type……………………………………………………………. 4-29
4.4.2 Molecular testing laboratory revenues ……………………………………………….. 4-32
4.5 Bibliography………………………………………………………………………………………………………….. 4-34
Exhibit 4-1: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), 2017-22 …………………………………………………………………………………………………….4-3
Exhibit 4-2: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by region, 2017-22 …………………………………………………………………………………………….. 4-4
Exhibit 4-3: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by type of cancer, 2017-22………………………………………………………………………………….. 4-8
Exhibit 4-4: Molecular in vitro diagnostic tests for breast cancer, global market forecast ($m), by region, 2017-22………………………………………………….. 4-10
Exhibit 4-5: Molecular in vitro diagnostic tests for prostate cancer, global market forecast ($m), by region, 2017-22………………………………………………….. 4-12
Exhibit 4-6: Molecular in vitro diagnostic tests for lung cancer, global market forecast ($m), by region, 2017-22………………………………………………….. 4-14
Exhibit 4-7: Global sales of targeted drugs used in lung cancer therapy ($m), 2015-17………………. 4-15
Exhibit 4-8: Molecular in vitro diagnostic tests for colorectal cancer, global market forecast ($m), by region, 2017-22………………………………………………….. 4-16
Exhibit 4-9: Global sales of targeted drugs used in colorectal cancer therapy ($m), 2015-17 ………………………………………………………………………………………………………….. 4-16
Exhibit 4-10: Molecular in vitro diagnostic tests for melanoma, global market forecast ($m), by region, 2017-22…………………………………………………. 4-18
Exhibit 4-11: Global sales of targeted drugs used in melanoma therapy ($m), 2015-17 ……………… 4-18
Exhibit 4-12: Molecular in vitro diagnostic tests for cervical cancer, global market forecast ($m), by region, 2017-22…………………………………………………. 4-21
Exhibit 4-13: Prevalence of human papilloma virus infection, by geographic region…………………… 4-21
Exhibit 4-14: Molecular in vitro diagnostic tests for leukemia/lymphoma, global market forecast ($m), by region, 2017-22…………………………………………………. 4-23
Exhibit 4-15: Molecular in vitro diagnostic tests for other cancer types, global market forecast ($m), by region, 2017-22…………………………………………………. 4-26
Exhibit 4-16: Molecular in vitro diagnostic tests for oncology, share by supplier ($m), 2017………………………………………………………………………………………………………………. 4-29
Exhibit 4-17: Molecular in vitro diagnostic tests for oncology, company sales by cancer type ($m), 2017 ………………………………………………………….. 4-31
Exhibit 4-18: Molecular oncology in vitro diagnostic testing services market ($m), 2017………………………………………………………………………………………………………………. 4-33
APPENDIX: COMPANY LISTING……………………………………………………………………………………………………..A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!